Should I buy or sell Puma Biotechnology stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBYI shares. View PBYI analyst ratings or view top-rated stocks .

What is Puma Biotechnology's stock price target for 2024?

1 analysts have issued 12 month price targets for Puma Biotechnology's stock. Their PBYI share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 40.3% from the stock's current price. View analysts price targets for PBYI or view top-rated stocks among Wall Street analysts .

How have PBYI shares performed in 2024?

Puma Biotechnology's stock was trading at $4.33 on January 1st, 2024. Since then, PBYI stock has increased by 15.2% and is now trading at $4.99. View the best growth stocks for 2024 here .

When is Puma Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our PBYI earnings forecast .

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) announced its quarterly earnings results on Thursday, February, 29th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by $0.07. The biopharmaceutical company earned $72.20 million during the quarter, compared to analysts' expectations of $73.22 million. Puma Biotechnology had a trailing twelve-month return on equity of 58.21% and a net margin of 9.16%.

What guidance has Puma Biotechnology issued on next quarter's earnings?

Puma Biotechnology issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $214.0 million-$225.0 million, compared to the consensus revenue estimate of $244.7 million.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN) , BioMarin Pharmaceutical (BMRN) , Incyte (INCY) , First Solar (FSLR) , Dynavax Technologies (DVAX) , United Airlines (UAL) , (KITE) (KITE) , Array Technologies (ARRY) , Freeport-McMoRan (FCX) and

How do I buy shares of Puma Biotechnology?

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PBYI

Puma Biotechnology (PBYI) Stock Price, News & Analysis

→ [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad)

Free PBYI Stock Alerts

$4.99

-0.18 (-3.48%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.93
▼
$5.29
50-Day Range: $4.30
▼
$7.40
52-Week Range: $2.13
▼
$7.73

Volume: 289,054 shs
Average Volume: 573,195 shs
Market Capitalization: $240.57 million

P/E Ratio: 10.85
Dividend Yield: N/A
Price Target: $7.00

Get Puma Biotechnology alerts:

Puma Biotechnology MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 40.3% Upside
$7.00 Price Target
Short Interest: Bearish
9.54% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.30
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.52 out of 5 stars

Medical Sector

454th out of 919 stocks

Pharmaceutical Preparations Industry

198th out of 405 stocks

3.5

Analyst's Opinion

Consensus Rating
Puma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Puma Biotechnology has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
9.54% of the float of Puma Biotechnology has been sold short.
Short Interest Ratio / Days to Cover
Puma Biotechnology has a short interest ratio ("days to cover") of 5.4.
Change versus previous month
Short interest in Puma Biotechnology has recently decreased by 1.20%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Puma Biotechnology does not currently pay a dividend.
Dividend Growth
Puma Biotechnology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PBYI.

1.3

News and Social Media Coverage

News Sentiment
Puma Biotechnology has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Puma Biotechnology this week, compared to 2 articles on an average week.
Search Interest
Only 8 people have searched for PBYI on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Puma Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Puma Biotechnology insiders have not sold or bought any company stock.
Percentage Held by Insiders
22.70% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Puma Biotechnology are expected to remain at $0.29 per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Puma Biotechnology is 10.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.94.
Price to Earnings Ratio vs. Sector
The P/E ratio of Puma Biotechnology is 10.85, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 227.61.
Price to Earnings Growth Ratio
Puma Biotechnology has a PEG Ratio of 2.90. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Puma Biotechnology has a P/B Ratio of 4.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Puma Biotechnology Stock (NASDAQ:PBYI)

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

PBYI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PBYI Stock News Headlines

April 18, 2024 | businesswire.com

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

April 18, 2024 | americanbankingnews.com

Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200-Day Moving Average of $4.46

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 10, 2024 | americanbankingnews.com

Puma Biotechnology (NASDAQ:PBYI) Cut to "Hold" at StockNews.com

April 8, 2024 | finance.yahoo.com

Puma Biotechnology (NASDAQ:PBYI) shareholders have earned a 93% return over the last year

April 8, 2024 | americanbankingnews.com

Analysts Issue Forecasts for Puma Biotechnology, Inc.'s Q1 2024 Earnings (NASDAQ:PBYI)

April 3, 2024 | businesswire.com

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

March 22, 2024 | finance.yahoo.com

Do Puma Biotechnology's (NASDAQ:PBYI) Earnings Warrant Your Attention?

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 20, 2024 | markets.businessinsider.com

Puma Biotechnology: FDA Allows To Proceed With Clinical Development Of Alisertib

March 20, 2024 | finance.yahoo.com

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

March 2, 2024 | markets.businessinsider.com

Buy Rating on Puma Biotechnology Amid Financial Challenges and Drug Advancement Prospects

March 2, 2024 | finance.yahoo.com

Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Could Be 47% Below Their Intrinsic Value Estimate

March 2, 2024 | seekingalpha.com

Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript

February 29, 2024 | businesswire.com

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024 | finance.yahoo.com

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

February 27, 2024 | businesswire.com

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

February 22, 2024 | finance.yahoo.com

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference

February 22, 2024 | businesswire.com

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference

February 21, 2024 | msn.com

Puma Biotech (PBYI) Is Up 23.01% in One Week: What You Should Know

February 15, 2024 | finance.yahoo.com

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

February 15, 2024 | businesswire.com

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

February 13, 2024 | wsj.com

Puma Biotechnology Inc.

February 13, 2024 | finance.yahoo.com

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

February 9, 2024 | msn.com

PBYI vs. AMGN: Which Stock Should Value Investors Buy Now?

February 7, 2024 | finance.yahoo.com

Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up

February 5, 2024 | finance.yahoo.com

Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B

See More Headlines

Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PBYI
CUSIP: N/A
CIK: 1401667
Web: www.pumabiotechnology.com
Phone: (424) 248-6500
Fax: 424-248-6501
Employees: 185
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $7.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +36.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.46
Trailing P/E Ratio: 11.17
Forward P/E Ratio: 17.72
P/E Growth: 2.9
Net Income: $21.59 million
Net Margins: 9.16%
Pretax Margin: 9.62%
Return on Equity: 58.21%
Return on Assets: 10.40%

Debt

Debt-to-Equity Ratio: 1.23
Current Ratio: 1.57
Quick Ratio: 1.50

Sales & Book Value

Annual Sales: $235.60 million
Price / Sales: 1.05
Cash Flow: $0.70 per share
Price / Cash Flow: 7.33
Book Value: $1.12 per share
Price / Book: 4.59

Miscellaneous

Outstanding Shares: 48,210,000
Free Float: 37,264,000
Market Cap: $247.80 million
Optionable: Optionable
Beta: 1.28

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Alan H. Auerbach (Age 54)
Founder, Chairman, President, CEO & Secretary
Comp: $1.74M
Mr. Maximo F. Nougues (Age 55)
CFO & Principal Accounting Officer
Comp: $781.47k
Dr. Alvin F. Wong Pharm.d. (Age 71)
Chief Scientific Officer
Comp: $809.69k
Mr. Douglas Hunt B.Sc. (Age 59)
FRAPS, Senior Vice President of Regulatory Affairs, Pharmacovigilance, Medical Affairs & Law
Comp: $632.65k
Mr. Jeffrey Jerome Ludwig (Age 58)
Chief Commercial Officer
Comp: $916.85k
Mr. Mariann Ohanesian
Senior Director of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PBYI Stock Analysis - Frequently Asked Questions

Should I buy or sell Puma Biotechnology stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBYI shares.
View PBYI analyst ratings or view top-rated stocks.
What is Puma Biotechnology's stock price target for 2024?: 1 analysts have issued 12 month price targets for Puma Biotechnology's stock. Their PBYI share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 40.3% from the stock's current price.
View analysts price targets for PBYI or view top-rated stocks among Wall Street analysts.
How have PBYI shares performed in 2024?: Puma Biotechnology's stock was trading at $4.33 on January 1st, 2024. Since then, PBYI stock has increased by 15.2% and is now trading at $4.99.
View the best growth stocks for 2024 here.
When is Puma Biotechnology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PBYI earnings forecast.

How were Puma Biotechnology's earnings last quarter?: Puma Biotechnology, Inc. (NASDAQ:PBYI) announced its quarterly earnings results on Thursday, February, 29th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by $0.07. The biopharmaceutical company earned $72.20 million during the quarter, compared to analysts' expectations of $73.22 million. Puma Biotechnology had a trailing twelve-month return on equity of 58.21% and a net margin of 9.16%.
What guidance has Puma Biotechnology issued on next quarter's earnings?: Puma Biotechnology issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $214.0 million-$225.0 million, compared to the consensus revenue estimate of $244.7 million.
What other stocks do shareholders of Puma Biotechnology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and
How do I buy shares of Puma Biotechnology?: Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PBYI) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Puma Biotechnology (PBYI) Stock Price, News & Analysis

Puma Biotechnology MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Puma Biotechnology Stock (NASDAQ:PBYI)

PBYI Stock Price History

PBYI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PBYI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™